Rhelion Life Sciences Corp. (CSE: RHEL) has announced that its wholly owned subsidiary Filament Health Corp. has shipped its patented botanical psilocybin drug candidate PEX010™ to King's College London to supply the SLEEPY feasibility study. The study will evaluate a method of administering psilocybin just before sleep to assess whether participants can determine if they received the drug, a blinding challenge common in psychedelic research. The shipment marks another institutional milestone for Filament, which the company states now supports more than 80 academic and philanthropic research studies worldwide.

Key Points

  • Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF)
  • Filament Health has shipped PEX010™ to King's College London for the SLEEPY feasibility study (ISRCTN10648713)
  • PEX010™ is available in standardised doses of 1, 5, and 25 mg, with a 0.5 mg dose to follow; Filament completed its acquisition by Rhelion on April 30, 2026
  • Investors may be watching for further institutional supply agreements and progress on the 0.5 mg dose development

SLEEPY Study Design and King's College London Partnership

The SLEEPY study — formally titled "Sleep Blinding Psilocybin: A feasibility study" — is led by Dr. Raphael Rifkin-Zybutz at King's College London. King's College London and South London and Maudsley NHS Foundation Trust are named as the study's sponsors. The study will test whether administering psilocybin just before sleep prevents healthy volunteers from identifying whether they received the drug, addressing a known methodological limitation in psychedelic clinical research. Rhelion's disclosure states that Filament is a supplier to the study and is not the sponsor, and therefore is not responsible for the study's conduct.

PEX010 Drug Candidate and Filament's Global Research Supply Role

PEX010™ is Filament Health's patented, standardised, GMP-manufactured botanical psilocybin drug candidate produced using the company's proprietary extraction, purification, and stabilisation methods. The release states it is available in 1, 5, and 25 mg doses from a single drug candidate, with a 0.5 mg dose in development. Rhelion states that PEX010™ now supports more than 80 academic and philanthropic research studies globally, positioning Filament as a leading supplier of pharmaceutical-grade natural psilocybin to institutions worldwide.

Filament Health Acquisition and Intellectual Property Portfolio

Rhelion completed its acquisition of Filament Health Corp. on April 30, 2026, gaining access to PEX010™ and a portfolio of 78 issued patents across 13 patent families. The release describes Rhelion as an Ontario-based organisation advancing innovation within the legal psychedelic sector. The SLEEPY shipment represents one of the first announced institutional supply activities conducted under the combined entity, and investors may be watching for further developments as Rhelion integrates Filament's clinical infrastructure and intellectual property into its operations.